Velho et al. reported that germline DNA-repair gene mutation-positive prostate cancer patients (52% BRCA1 or BRCA2) had lower median PSA levels at diagnosis than mutation-negative patients. This evidence concerns the gene BRCA2 and Familial prostate cancer.